University of California Irvine
University of California Irvine
Irvine, California, United States30 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258) | Acute Decompensated Heart Failure | Recruiting | Phase 3 | 2026-10-08 | NCT06898515 | |
| Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Recruiting | Phase 1 | 2026-10-08 | NCT05919238 | |
| A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | acquired idiopathic inflammatory myopathy, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease | Not yet recruiting | Phase 3 | 2026-09-30 | NCT07789015 | |
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | Active, not recruiting | Phase 3 | 2026-09-21 | NCT04586010 | |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | NonSegmental Vitiligo | Recruiting | Phase 3 | 2026-09-14 | NCT06548360 | |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-09 | NCT06854653 | |
| Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) | autosomal recessive limb-girdle muscular dystrophy type 2I | Active, not recruiting | Phase 3 | 2026-09-09 | NCT05775848 | |
| Multicenter Single-Blind RCT of CTIF Versus LNF For Treatment of GERD in Patients Requiring Hiatal Hernia Repair | Deglutition Disorders, Digestive System Diseases, Hernia, Hernia, Diaphragmatic, Internal Hernia, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, digestive system disorder, dyskinesia of esophagus, esophageal disorder, gastroesophageal reflux disease, hiatus hernia | Active, not recruiting | Not applicable | 2026-09-03 | NCT04795934 | |
| A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum | Skin Ulcer, Skin and Connective Tissue Diseases, pyoderma, pyoderma gangrenosum, skin disorder, skin vascular disease | Recruiting | Phase 3 | 2026-09-02 | NCT06624670 | |
| A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, generalized pustular psoriasis, psoriasis, skin disorder | Active, not recruiting | Phase 4 | 2026-09-02 | NCT06013969 | |
| A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fabry disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, X-linked disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT03737214 | |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Relapsing Multiple Sclerosis | Recruiting | Phase 3 | 2026-08-26 | NCT06846281 | |
| A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | NonSegmental Vitiligo | Active, not recruiting | Phase 3 | 2026-08-25 | NCT06113445 | |
| Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | Myasthenia Gravis, Generalized, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 2 | 2026-08-14 | NCT04146051 | |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | Relapsing Multiple Sclerosis (RMS) | Active, not recruiting | Phase 3 | 2026-08-10 | NCT06869785 | |
| Neural Bases of Vocal Sensorimotor Impairment in Aphasia | Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, aphasia, communication disorder, language disorder, nervous system disorder, speech disorder | Recruiting | Not applicable | 2026-07-28 | NCT04742894 | |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-07-24 | NCT04548999 | |
| Ceribell Delirium Monitor Outcomes Pilot Study | Confusion, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cognitive disorder, delirium, nervous system disorder, psychiatric disorder | Recruiting | Not applicable | 2026-07-22 | NCT07449416 | |
| Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST) | Embolism, Embolism and Thrombosis, cardiovascular disorder, lung disorder, pulmonary embolism, respiratory system disorder, vascular disorder | Recruiting | Not applicable | 2026-07-17 | NCT06041594 | |
| A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-07-08 | NCT05070858 | |
| A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-04-13 | NCT06146257 | |
| A Global Prospective Observational Registry of Patients With Pompe Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder | Recruiting | Not stated | 2026-03-10 | NCT06121011 | |
| GDNF Gene Therapy for Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Active, not recruiting | Phase 1 | 2026-01-30 | NCT04680065 | |
| AMP SCZ® Observational Study: PREDICT-DPACC | Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder | Active, not recruiting | Not stated | 2025-10-31 | NCT05905003 | |
| Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-10-22 | NCT06100276 |